Brief: Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients In Eliminating Mild To Moderate Covid-19 Symptoms Within The 6-Day Treatment Period In Its Earth Efficacy Trial

Regencell Bioscience Holdings

17/02/2022 01:47

Feb 16 (Reuters) - Regencell Bioscience Holdings Ltd
 RGC.O :
    * REGENCELL BIOSCIENCE’S INVESTIGATIONAL LIQUID-FORMULA
RGC-COV19TM SHOWS EFFECTIVENESS THROUGH ITS ENROLLED PATIENTS IN
ELIMINATING MILD TO MODERATE COVID-19 SYMPTOMS WITHIN THE 6-DAY
TREATMENT PERIOD IN ITS EARTH EFFICACY TRIAL
    * RESULTS HAVE YET TO BE PEER REVIEWED
    * EARTH WAS A NON-BLINDED EFFICACY TRIAL CONDUCTED FROM 1
OCTOBER
2021 UNTIL 31 JANUARY 2022.

Source text for Eikon:  ID:nBw6Zbyv8a 
Further company coverage:  RGC.O 

 ((Reuters.Briefs@thomsonreuters.com;))